Hatch-Waxman and BPCIA Overview

March 12, 2014

New York, NY

As part of the American Conference Institute’s 22nd Annual FDA Boot Camp, Zuckerman Spaeder LLP partner Carlos Angulo participated in a discussion of biosimilar pharmaceutical products in the context of the Drug Price Competition and Patent Term Restoration Act, known as the Hatch-Waxman Act, and the Biosimilar Price Competition and Innovation Act (BPCIA). Mr. Angulo, whose practice focuses on food and drug law, gave a comprehensive overview of biosimilars, in addition to providing insight on bioequivalence and exclusivities.